Cancer Clinical Trial - Revolution Medicines RMC-4630-01

Status:

Open

ClinicalTrials.gov:

NCT03634982

CONDITION(S): Lung, NSCLC - TRIAL: Revolution Medicines RMC-4630-01 - Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-4630 monotherapy in adult participants with relapsed/refractory solid tumors and to identify the recommended Phase 2 dose (RP2D).

Drug

RMC-4630

Trial Type

Interventional

Condition

Lung cancer Non-small cell lung cancer (NSCLC)

Keywords

Lung cancer | Non-small cell lung cancer (NSCLC) | RMC-4630